Notice Pursuant to the National Cooperative Research and Production Act of 1993-Rapid Response Partnership Vehicle, 82631 [2024-23591]

Agencies

• Antitrust Division
• Department of Justice

[Federal Register Volume 89, Number 198 (Friday, October 11, 2024)]
[Notices]
[Page 82631]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-23591]



[[Page 82631]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Rapid Response Partnership Vehicle

    Notice is hereby given that, on July 11, 2024, pursuant to section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), Rapid Response Partnership 
Vehicle (``RRPV'') has filed written notifications simultaneously with 
the Attorney General and the Federal Trade Commission disclosing 
changes in its membership. The notifications were filed for the purpose 
of extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances.
    Specifically, Esperovax, Inc., Plymouth, MI; Genomic Expression, 
Inc., Beverly, MA; ID Biologics, Inc., Nashville, TN; MPS Medical, 
Inc., Brea, CA; QuidelOrtho Corp., San Diego, CA; Sinergium Biotech 
S.A., Buenos Aires, ARGENTINA; Somatek, San Diego, CA; True 
Diagnostics, Inc., Carlsbad, CA; VaxSyna, Inc., Franklin, NH; Burrell 
International Group LLC, Washington, DC; Cellular Technology, Ltd., 
Shaker, OH; QIAGEN LLC, Germantown, MD; RAIsonance, Inc., Greenwood 
Village, CO; Canaria Technologies Pty, Ltd., Brisbane, AUSTRALIA; 
Elarex, Inc., Burlington, CANADA; Gila Diagnostics, Inc., Phoenix, AZ; 
IIT Research Institute, Chicago, IL; ImmunoServ, Cardiff, UNITED 
KINGDOM; OraSure Technologies, Inc., Bethlehem, PA; Vaccine Company, 
Inc., Bethesda, MD; Visby Medical, Inc., San Jose, CA; Global Life 
Science Solutions USA LLC dba Cytiva, Marlborough, MA; Pathway Policy 
Group LLC, McLean, VA; PSC Biotech Corporation, Pomona, CA; Q-VANT 
Biosciences, Inc., Forestdale, MA; Seqirus, Inc., Holly Springs, NC; 
The Rector and Visitors of the University of Virginia, Charlottesville, 
VA; Gusmer Enterprises, Inc., Mountainside, NJ; Azure Medical, Inc., La 
Verne, CA; Cellphire Therapeutics, Inc., Rockville, MD; CorDx, Inc., 
San Diego, CA; The University of Central Florida Board of Trustees, 
Orlando, FL; The Albert B. Sabin Vaccine Institute, Inc., Washington, 
DC; InFlo Medical, Irvine, CA; Shionogi, Inc., Florham Park, NJ; Agno 
Pharmaceuticals LLC, Bethlehem, PA; Astute Crew LLC, San Lorenzo, CA; 
CONTINUUS Pharmaceuticals, Inc., Woburn, MA; Cornerstone Government 
Affairs, Inc., Washington, DC; Cytophage Technologies, Inc., Winnipeg, 
CANADA; Decoy Therapeutics, Cambridge, MD; Emergex USA Corp., 
Doylestown, PA; Emergo Therapeutics, Chapel Hill, NC; GE Medical 
Systems Information Technologies, Inc. dba GE Healthcare Technology & 
Innovation Center, Niskayuna, NY; GRI Technology Solutions LLC, San 
Mateo, CA; Humanetics Corp., Minneapolis, MN; North X Biologics AB, 
Matfors, SWEDEN; Novavax, Inc., Gaithersburg, MD; Photosynthetic B.V., 
Amsterdam, NETHERLANDS; Pioneer Vaccine, Inc., Daejeon, REPUBLIC OF 
KOREA; Quantiscope PBC, Salt Lake City, UT; Validated Cloud, Inc., 
Waltham, MA; Vivaldi Biosciences, Inc., Fort Collins, CO; Wheeler Bio, 
Inc., Oklahoma, OK; A-Alpha Bio, Inc., Seattle, WA; Prosetta 
Biosciences, Inc., San Francisco, CA; Revagenix, Inc., San Francisco, 
CA; University of Texas Medical Branch at Galveston, Galveston, TX; 
AlbaNY labs LLC, Rensselaer, NY; AI Proteins, Inc., Boston, MA; Appel 
Sauce Studios LLC, Menlo Park, CA; Microbiologics, Inc., Saint Cloud, 
MN; POP Biotechnologies, Buffalo, NY; Southern Research Institute, 
Birmingham, AL; and SPOC Proteomics, Inc., Scottdale, AZ, have been 
added as parties to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and RRPV intends to file additional 
written notifications disclosing all changes in membership.
    On January 05, 2024, RRPV filed its original notification pursuant 
to section 6(a) of the Act. The Department of Justice published a 
notice in the Federal Register pursuant to section 6(b) of the Act on 
April 16, 2024 (89 FR 26928).
    The last notification was filed with the Department on April 12, 
2024. A notice was published in the Federal Register pursuant to 
section 6(b) of the Act on June 21, 2024 (89 FR 52095).

Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-23591 Filed 10-10-24; 8:45 am]
BILLING CODE P